Ascletis\'s Second HCV Treatment on Priority Review List in China

Ascletis's Second HCV Treatment on Priority Review List in China

Ascletis Pharma of Hangzhou reported that its second hepatitis C treatment, ravidasvir, has been included in China's list of Proposed Priority Review drugs. Ascletis has submitted an NDA for ravidasvir, a China Category 1 candidate, as part of a two-drug combination treatment, along with already-approved Ganovo®. The combination, an all-oral interferon-free regimen, produced a 99% cure rate in HCV patients after only 12 weeks of treatment in a China Phase II/III trial. Ascletis launched Ganovo three months ago, soon after approval. More details....

Stock Symbol: (HK; 1672)

Share this with colleagues:

Original Article: Ascletis's Second HCV Treatment on Priority Review List in China

More From BioPortfolio on "Ascletis's Second HCV Treatment on Priority Review List in China"